In a non-randomized study, the efficacy and safety of the CV9202 vaccine administered in combination with durvalumab (anti-PD-L1 antibody) and tremelimumab (anti-CTLA-4 antibody) were evaluated in patients with NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.